These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 32956756

  • 21. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
    Bernstein JA, Virchow JC, Murphy K, Maspero JF, Jacobs J, Adir Y, Humbert M, Castro M, Marsteller DA, McElhattan J, Hickey L, Garin M, Vanlandingham R, Brusselle G.
    Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
    [Abstract] [Full Text] [Related]

  • 22. Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood.
    Schwarz C, Müller T, Lau S, Parasher K, Staab D, Wahn U.
    Pediatr Allergy Immunol; 2018 Feb; 29(1):28-33. PubMed ID: 28986919
    [Abstract] [Full Text] [Related]

  • 23. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
    Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P.
    Lancet; 2012 Aug 18; 380(9842):651-9. PubMed ID: 22901886
    [Abstract] [Full Text] [Related]

  • 24. Mepolizumab in Hypereosinophilic Syndrome: A Systematic Review and Meta-analysis.
    Alves Júnior JM, Prota FE, Villagelin D, Bley F, Bernardo WM.
    Clinics (Sao Paulo); 2021 Aug 18; 76():e3271. PubMed ID: 34644737
    [Abstract] [Full Text] [Related]

  • 25. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T, Milan SJ, Wang R, Banchoff E, Bradley P, Crossingham I.
    Cochrane Database Syst Rev; 2020 Dec 08; 12(12):CD013432. PubMed ID: 33295032
    [Abstract] [Full Text] [Related]

  • 26. Mepolizumab treatment in patients with severe eosinophilic asthma.
    Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P, MENSA Investigators.
    N Engl J Med; 2014 Sep 25; 371(13):1198-207. PubMed ID: 25199059
    [Abstract] [Full Text] [Related]

  • 27. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
    Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Barros M, Buhl R, Howarth P, Albers FC, Bradford ES, Gilson M, Price RG, Yancey SW, Ortega H.
    J Allergy Clin Immunol; 2019 May 25; 143(5):1742-1751.e7. PubMed ID: 30359681
    [Abstract] [Full Text] [Related]

  • 28. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial.
    Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S, Durham SR, Cornet ME, Kariyawasam HH, Gilbert J, Austin D, Maxwell AC, Marshall RP, Fokkens WJ.
    J Allergy Clin Immunol; 2017 Oct 25; 140(4):1024-1031.e14. PubMed ID: 28687232
    [Abstract] [Full Text] [Related]

  • 29. Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count.
    Bachert C, Sousa AR, Han JK, Schlosser RJ, Sowerby LJ, Hopkins C, Maspero JF, Smith SG, Kante O, Karidi-Andrioti DE, Mayer B, Chan RH, Yancey SW, Chaker AM.
    J Allergy Clin Immunol; 2022 May 25; 149(5):1711-1721.e6. PubMed ID: 35007624
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.
    Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M, SIROCCO study investigators.
    Lancet; 2016 Oct 29; 388(10056):2115-2127. PubMed ID: 27609408
    [Abstract] [Full Text] [Related]

  • 32. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
    Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK, Beck LA, Boyce JA, Filipovich AH, Villanueva JM, Sutton SA, Assa'ad AH, Rothenberg ME.
    J Allergy Clin Immunol; 2004 Jan 29; 113(1):115-9. PubMed ID: 14699394
    [Abstract] [Full Text] [Related]

  • 33. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, Smith SG, Martin N, Mayer B, Yancey SW, Sousa AR, Chan R, Hopkins C, SYNAPSE study investigators.
    Lancet Respir Med; 2021 Oct 29; 9(10):1141-1153. PubMed ID: 33872587
    [Abstract] [Full Text] [Related]

  • 34. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma.
    Albers FC, Licskai C, Chanez P, Bratton DJ, Bradford ES, Yancey SW, Kwon N, Quirce S.
    Respir Med; 2019 Nov 29; 159():105806. PubMed ID: 31751853
    [Abstract] [Full Text] [Related]

  • 35. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
    Busse WW, Ring J, Huss-Marp J, Kahn JE.
    J Allergy Clin Immunol; 2010 Apr 29; 125(4):803-13. PubMed ID: 20371394
    [Abstract] [Full Text] [Related]

  • 36. Prospective Open-Label Study of 48-Week Subcutaneous Administration of Mepolizumab in Japanese Patients With Severe Eosinophilic Asthma.
    Kurosawa M, Sutoh E.
    J Investig Allergol Clin Immunol; 2019 Apr 29; 29(1):40-45. PubMed ID: 29957591
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of ≥150-300 cells/μL.
    Yancey SW, Bradford ES, Keene ON.
    Respir Med; 2019 May 29; 151():139-141. PubMed ID: 31047111
    [Abstract] [Full Text] [Related]

  • 39. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A.
    Lancet; 2016 Jul 02; 388(10039):31-44. PubMed ID: 27130691
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.